Form 4: Altimmune Director Gill Reports Stock Option Grant

Altimmune Director John Gill reported the acquisition of 48,800 stock options and a gift of 2,714 common shares, adjusting his direct common stock ownership to zero.

Summary

• John Gill, a Director of Altimmune, Inc. (ALT), reported changes in his beneficial ownership of company securities.
• On January 6, 2022, Gill made a bona fide gift of 2,714 shares of Altimmune common stock.
• Previous Section 16 reports inadvertently overstated Gill's direct common stock ownership by 57 shares.
• As of the date of this filing, Gill does not hold any shares of common stock directly or indirectly.
• On September 25, 2025, Gill acquired 48,800 stock options with an exercise price of $3.92 per share.
• These stock options will vest in substantially equal monthly installments over 12 months following September 25, 2025, contingent on Gill's continued service.
• The acquired stock options have an expiration date of September 25, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the significant grant of stock options, which aligns the director's long-term interests with the company. However, the reduction of direct common stock ownership to zero introduces a neutral to slightly negative aspect.

Positives

• The grant of 48,800 stock options to Director John Gill aligns his incentives with long-term company performance, as the options vest over 12 months and have a 10-year expiration.

Negatives

• Director John Gill's direct and indirect beneficial ownership of common stock is now zero following a gift of 2,714 shares and a correction of previous reporting errors, which may be perceived as a reduced direct equity stake in the company.

Future Outlook

The 48,800 stock options granted to Director John Gill will vest in substantially equal monthly installments over the 12 months following September 25, 2025, subject to his continued service to the company.

Industry Context

This filing is a routine insider transaction report, common across all publicly traded companies, reflecting changes in a director's personal holdings and compensation structure. It does not provide information on broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Provides transparency into a director's equity holdings and compensation, showing alignment through stock options but a lack of direct common stock ownership.

Next Steps

• The 48,800 stock options will begin vesting in substantially equal monthly installments over 12 months starting September 25, 2025.

Key Dates

Keywords

Altimmune, ALT, John Gill, Director, Stock Options, Insider Transaction, Beneficial Ownership, SEC Form 4, Equity Compensation